• Nem Talált Eredményt

18 eredmény a kulcsszóra: 'epidermal growth factor egf'

Jelátviteli molekulák szerepe a petesejtek maturációjában és a korai embriófejlődésben (Irodalmi összefoglalás) megtekintése

The author has examined the effect of the signal transduction molecules as: IGF ((Insulin-like Growth Factor), EGF (Epidermal Growth Factor), VEGF (Vascular Endothelia Growth

Protected

N/A

12
0
0
2022
HUMAN EPIDERMAL GROWTH FACTOR

At indicated times thereafter duplicate dishes from cultures growing in the presence (o) or absence (·) of hEGF were removed and the cell numbers determined. At the times

Protected

N/A

23
0
0
2022
Az EGF-receptor és a claudinok expressziós mintázatának vizsgálata a fej-nyak régió laphámrákjaiban

(2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. (2007) Epidermal growth factor receptor copy number

Protected

N/A

90
0
0
2022
NYUGAT-MAGYARORSZÁGI EGYETEM MEZ

(1993) Effects of epidermal growth factor, insulin-like growth factor-I, and dialysed porcine follicular fluid on porcine oocyte maturation in vitro. (1988) Coculture

Protected

N/A

131
0
0
2022
Neil Selwyn: Education and Technology – key issues and debates (New York: Bloomsbury Academic. 2017. 216 p.)

In Education and Technology – key issues and debates Neil Selwyn summarises current and highly-disputed topics in the field of educational technology.. It explores problem

Protected

N/A

2
0
0
2022
Malignus kevert Müller-cső-eredetű tumor komplex kezelése

DFS = (disease-free survival) betegségmentes túlélés; EGFR = (epidermal growth factor receptor) epidermális növekedési fak- tor receptor; EMA = epithelialis membránantigén; FIGO =

Protected

N/A

7
0
0
2022
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187

Binding interactions between human serum albumin (HSA) and four approved epidermal growth factor receptor (EGFR) inhibitors gefitinib (GEF), erlotinib (ERL), afatinib (AFA),

Protected

N/A

26
0
0
2022
Studying EGFR-receptor and claudin expression patterns in head and neck squamous cell carcinomas PhD thesis Balázs Szabó MD Semmelweis University Doctoral School of Pathological Sciences

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. ORAL

Protected

N/A

18
0
0
2022
Supporting Information Conventional or mechanochemically-aided intercalation of diclofenac and naproxen anions into the interlamellar space of CaFe-layered double hydroxides and their application as dermal drug delivery systems

S1 X-ray diffractometry patterns of diclofenac anion-intercalated LDH samples intercalated in ethanol-water mixtures of varying compositions (1:1 Fe(III):diclofenac

Protected

N/A

12
0
0
2022
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study

Aim To evaluate (I) trastuzumab-containing primary systemic therapy (PST) in human epidermal growth factor receptor 2 (Her2) overexpressing breast carcinomas.; (II)

Protected

N/A

11
0
0
2022
Epidermal Growth Factor is E ff ective in the Treatment of Diabetic Foot Ulcers: Meta-Analysis and

Logit regression on the correlation between the recombinant human epidermal growth factor (rhEGF) application frequency (horizontal axis—measured in weeks) and complete healing

Protected

N/A

13
0
0
2022
Molecular testing in lung cancer in the era of precision medicine

When epidermal growth factor receptor (EGFR) mutation was detected in patients with pulmonary adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors

Protected

N/A

10
0
0
2022
Génexpresszió alapú prediktív biomarkerek a szolid tumorok szisztémás terápiájában

(2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical cancer research :

Protected

N/A

113
0
0
2022
Novel kinase inhibitor compounds for combination cancer therapy

(2013) Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.. Tanizaki

Protected

N/A

128
0
0
2022
EPIDEMIOLOGY AND CLINICAL RELEVANCE OF SUBTYPE-SPECIFIC KRAS AND EGFR MUTATIONS IN LUNG ADENOCARCINOMA

(2012) Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer

Protected

N/A

109
0
0
2022
KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth

Protected

N/A

8
0
0
2022
EPIDERMAL GROWTH FACTOR-INDUCED HYDROGEN PEROXIDE PRODUCTION IS MEDIATED BY DUAL OXIDASE 1 Gábor Sirokmány

(E) HaCaT cells were stimulated with thapsigargin in the presence of 600 or 1200 U/ml catalase and then processed for Trx1 western blot as described above. This experiment

Protected

N/A

31
0
0
2022
SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells

by SETD3 but is also regulated by a wide range of factors such as c-Myc, H-Ras, N-Ras, EGFR (epidermal growth factor receptor), ErbB1, HER2/Neu (ErbB2), Notch1, STAT3

Protected

N/A

16
0
0
2022

Töltsön fel további dokumentumokat, és töltse le azonnal az anyagtanulmányokat!